Amgen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. We're very pleased to welcome Amgen. Joining us today from the company, we have Peter Griffith, who is Executive Vice President and CFO; Dave Reese, who's Executive Vice President and Head of R&D; and Arvind Sood, who's Vice President and Head of Investor Relations. Thank you very much, gentlemen, for joining us today. We really appreciate your time. And so first, I'm going to turn it over to Peter and Dave to make some opening remarks before we launch into questions.
Terence, thank you very much, and thank you to Goldman Sachs. In the midst of the unprecedented COVID-19 pandemic, our focus remains on the safety of our employees and their families and continuing to reliably supply our medicines to patients across the globe. Dave and I, led by our CEO, Bob Bradway, have reached out to any number of our employees regarding the current climate in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
